Commerce Ministry sets up 'India-Japan pharma alliance' in Japan.

With a view to represent the demands of the Indian pharma companies in Japan, the Pharmaceutical Export Promotion Council of India (Pharmexcil), set up by ministry of commerce and and industry, recently constituted an indigenous body called India-Japan pharma alliance in Japan. This body will be acting as the Pharmexcil's front agency to represent the issues and the challenges faced by the Indian pharmaceutical companies in Japan.

This strategic decision highlights the governments initiatives in strengthening its business relation with respect to pharmaceutical segment in Japan. The decision to set up this body was taken after the completion of the CPhI Japan in which Pharmexcil through its India pavilion had successfully represented 'brand India' in the Japanese market.

According to Dr P V Appaji, director general (DG), Pharmexcil, “With respect to exports, Japan has a huge potential for growth in the generic segment that will provide an excellent business opportunity for the Indian generic pharma companies. Thus it is imperative that we strengthen this relation which is mutually beneficial for both the countries by providing a platform that will help us in understanding the industry dynamics of Japan, so that we can take requisite steps to help and guide Indian companies in doing their business in the country.”

Through this body, Pharmexcil plans to gauge and analyse the Japanese market more closely so that they will b able to address the issues and the challenges of the Indian companies that are based in Japan more aptly. The main aim of this body will be to give important regulatory guidance to the Indian companies interested in establishing business in Japan and to help them overcome their challenges in doing so.

Dr Appaji informed that to further boost the trade between the two countries Pharmexcil is already in discussions with the Japanese generic associations
to explore business opportunities with them in Japan. He stressed that this will be a very  important partnership as it will also act as a catalyst to many other collaborations between the two countries with respect to trade and commerce.

“Our main aim is to ensure and provide growth opportunities to the Indian companies by supporting them in their export initiatives. Apart from that, it is our vision to make the 'made in India' label strong and reputed brand in the international market for which we have been constantly tying-up with international agencies for better representation and visibility. We are extremely happy with the kind of response that we have received from CPhI Japan as over 80 pharma executives from about 12 to 15 Indian companies were able to showcase their products at the CPhI event highlighting our strengths to the Japanese market and we hope to continue this momentum by participating at the first CPhI South East Asia with our India pavilion,” he added.

Taking ahead from CPhI Japan, Pharmexcil has again teamed up with CPhI  by participating and having a India Pavilion at CPhI South East Asia (SEA), in Indonesia from May 10 to 12 this year. CPhI SEA is being organised for the first time by the organisers and is being held in Jakarta.

Source : pharmabiz.com